Quantitative X-ray computed tomography peritoneography in malignant peritoneal mesothelioma patients receiving intraperitoneal chemotherapy

scientific article published on 24 May 2013

Quantitative X-ray computed tomography peritoneography in malignant peritoneal mesothelioma patients receiving intraperitoneal chemotherapy is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1041515952
P356DOI10.1245/S10434-013-2976-8
P932PMC publication ID3853374
P698PubMed publication ID23702640
P5875ResearchGate publication ID236907613

P2093author name stringJohn A Chabot
Joseph H Graziano
Binsheng Zhao
Jing Qi
Sharyn N Lewin
Lawrence H Schwartz
Saravanan Krishnamoorthy
John D Allendorf
Gleneara E Bates
Joshua C Leinwand
Robert N Taub
Vesna N Slavkovic
Xiaotao Guo
P2860cites workIntraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancerQ24235235
Malignant mesothelioma: facts, myths, and hypothesesQ28390539
Prediction of creatinine clearance from serum creatinineQ29615603
Intraperitoneal cisplatin and cytarabine in the treatment of refractory or recurrent ovarian carcinomaQ33386934
Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma.Q33476440
Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005.Q33489828
Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancerQ34055165
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.Q34543902
Intraperitoneal antineoplastic drug delivery: rationale and resultsQ35121705
The transport barrier in intraperitoneal therapyQ36030299
Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancerQ36079934
Nonpleural mesotheliomas: mesothelioma of the peritoneum, tunica vaginalis, and pericardiumQ36329816
Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamicsQ39668452
Intraperitoneal distribution imaging in ovarian cancer patientsQ39936525
Intraperitoneal therapy for treatment of malignant disease principally confined to the peritoneal cavityQ40847045
Combination intraperitoneal chemotherapy with cisplatin, cytarabine, and doxorubicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavityQ42251780
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.Q43703526
Population-based survival for malignant mesothelioma after introduction of novel chemotherapyQ44469531
Intraperitoneal carboplatin and etoposide for persistent epithelial ovarian cancer: analysis of results by prior sensitivity to platinum-based regimens.Q46039128
Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitonealQ46646219
Intraperitoneal therapy for ovarian cancer: analysis of fluid distribution by computerized tomographyQ46770111
Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.Q51301047
Intraperitoneal cisplatin and paclitaxel in ovarian cancer.Q53263238
Computed tomographic peritoneography prior to intraperitoneal chemotherapy in advanced Müllerian cancer: a pilot study.Q53298632
Simplified calculation of body-surface area.Q55060911
Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group studyQ67520718
Computed tomographic assessment of intraperitoneal fluid distribution prior to intraperitoneal chemotherapy for ovarian cancerQ68119161
Pharmacokinetics of carboplatin after intraperitoneal administrationQ68126770
Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot StudyQ70790917
Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv routeQ71228870
Intraperitoneal cisplatin with systemic thiosulfate protectionQ71842628
Prediction of effectiveness of intraperitoneal chemotherapy by intraperitoneal scintigraphy in patients with advanced ovarian carcinomaQ72712533
Peritoneal mesotheliomaQ74654753
Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosisQ78743915
Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesotheliomaQ80980814
Two-stage operative cytoreduction and intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma: Operative morbidity and mortality in phase I and II trialsQ84624651
Clinical pharmacology of intraperitoneal cisplatinQ93605817
P275copyright licenseCreative Commons Attribution 2.0 GenericQ19125117
P6216copyright statuscopyrightedQ50423863
P921main subjectchemotherapyQ974135
peritoneal mesotheliomaQ7168876
P304page(s)S553-9
P577publication date2013-05-24
P1433published inAnnals of Surgical OncologyQ2853069
P1476titleQuantitative X-ray computed tomography peritoneography in malignant peritoneal mesothelioma patients receiving intraperitoneal chemotherapy
P478volume20 Suppl 3

Reverse relations

cites work (P2860)
Q38261500Advances in malignant peritoneal mesothelioma
Q39395657Does breast MRI background parenchymal enhancement indicate metabolic activity? Qualitative and 3D quantitative computer imaging analysis
Q38917015Preventing recurrence of diffuse malignant peritoneal mesothelioma
Q36874468Quantitative 3D breast magnetic resonance imaging fibroglandular tissue analysis and correlation with qualitative assessments: a feasibility study

Search more.